# Axelopran for Advanced Cancer in Patients Receiving Opioids

Source: https://onco.cc/trials/nct07354919/  
OnCo record `nct07354919` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by HealthPartners Institute, now recruiting.

## Summary

Axelopran for Advanced Cancer in Patients Receiving Opioids is a phase 2, interventional study registered as NCT07354919 by HealthPartners Institute, with a registry enrolment figure of 34 participants, started 2026-04-27 and due to reach its primary completion in 2027-11-01. Interventions recorded: axelopran. Conditions listed: Breast Cancer; Lung Cancer; Pancreas Cancer; Prostate Cancer. Primary outcome: Objective response rate (including complete response and partial response). Pancreatic eligibility wording from the registry: "Histologically or cytologically proven cancer of the prostate (carcinoma), breast (carcinoma), pancreas (carcinoma), and lung (non-small cell lung carcinoma (NSCLC)) that has relapsed or progressed on or after a standard systemic treatment that has included cytotoxic chemotherapy". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: AxeCan
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07354919
- Phase: 2
- Setting: A Phase II Trial of Cancer Response Using Axelopran in Patients With Advanced Cancers on Opioids (AxeCan)
- Sponsor: HealthPartners Institute
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT07354919: https://clinicaltrials.gov/study/NCT07354919

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07354919.json